ivosidenib

Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia

Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.

FDA Approves Abbott CDx, Agios Drug for AML Patients With IDH1 Mutation

This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.

ivosidenib

Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia

FDA Approves Abbott CDx, Agios Drug for AML Patients With IDH1 Mutation

Cerebral Palsy Sequencing Study Finds Clinically Actionable Alterations

Lucid Diagnostics Raises $22M in Convertible Debt Refinancing

Medicover Genetics Receives IVDR Certification for Genetic Testing Reagent Kit

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Multi-Ancestry Study Uncovers Genetic Contributors to Progressive Eye Disease